↓ Skip to main content

Generic cardiology drug prices: the potential benefits of the Marc Cuban cost plus drug company model

Overview of attention for article published in Frontiers in Pharmacology, August 2023
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (91st percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

twitter
34 X users

Readers on

mendeley
3 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Generic cardiology drug prices: the potential benefits of the Marc Cuban cost plus drug company model
Published in
Frontiers in Pharmacology, August 2023
DOI 10.3389/fphar.2023.1179253
Pubmed ID
Authors

Aparna Narendrula, Jacob Lang, Elias Mossialos

Timeline

Login to access the full chart related to this output.

If you don’t have an account, click here to discover Explorer

X Demographics

X Demographics

The data shown below were collected from the profiles of 34 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 3 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 3 100%

Demographic breakdown

Readers by professional status Count As %
Student > Doctoral Student 1 33%
Unknown 2 67%
Readers by discipline Count As %
Medicine and Dentistry 1 33%
Unknown 2 67%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 21. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 September 2023.
All research outputs
#1,849,517
of 26,563,001 outputs
Outputs from Frontiers in Pharmacology
#762
of 20,605 outputs
Outputs of similar age
#32,324
of 367,373 outputs
Outputs of similar age from Frontiers in Pharmacology
#10
of 697 outputs
Altmetric has tracked 26,563,001 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 20,605 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.5. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 367,373 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 697 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.